Cholinergic Drugs for Alzheimer's Disease

Name: Cholinergic Drugs for Alzheimer's Disease
Author: Cheorl-Ho Kim

From Central Cholinergic Neurotransmission to Drug Therapies and Natural Products with Multitarget Actions

Specificaties

Paperback, blz. | Engels

Elsevier Science | e druk, 2026

ISBN13: 9780443458446

Rubricering

Juridisch :

Elsevier Science e druk, 2026 9780443458446

€ 224,19

In winkelwagen

Levertijd ongeveer 9 werkdagen

Gratis verzonden

Samenvatting

Cholinergic Drugs for Alzheimer’s Disease: From Central Cholinergic Neurotransmission to Drug Therapies and Natural Products with Multitarget Actions addresses the urgent need for advanced resources in neuropharmacology. The first section presents mechanistic insights into cholinergic drugs, current hypotheses for Alzheimer’s Disease progression, neurotransmitter systems, receptor biology, and the evolution of acetylcholinesterase inhibitors, including hybrid and multi-target drugs. It also covers clinical status, neuromuscular blockers, non-adrenergic neurotransmitters, protein kinase inhibitors, inflammation modulation, NMDA antagonism, biomarkers, and AI-assisted drug discovery.

The second section explores natural alkaloidal and non-alkaloidal compounds, molecular docking, SAR analysis, and daily consumable resources, with the third section investigating marine-derived AChE inhibitors, dual- and multi-target drug concepts, and emerging therapeutic compounds. This book equips the scientific community with a robust foundation for understanding and innovating in Alzheimer’s Disease therapy. By integrating molecular biology, pharmacology, and computational approaches, it empowers researchers and clinicians to address treatment challenges, optimize drug design, and leverage natural products for multifactorial intervention.

Specificaties

ISBN13:9780443458446

Taal:Engels

Bindwijze:Paperback

Uitgever:Elsevier Science

Inhoudsopgave

Section 1. Cholinergic drugs for Alzheimer’s disease: Mechanisms, emerging and future evolution 1. Introduction 2. Current hypothesis for AD progression 3. Neurotransmitter (NT) systems and peripheral nerve system (PNS) 4. ACh receptors in ACh transmission 5. Choline esterase 6. Cholinergic ACh, AChE, and its inhibitors 7. Classification of ChE inhibitors by binding mode 8. Classification of ChE inhibitors by action mechanism 9. Clinical status of ChE inhibitors 10. AChE inhibitors 11. Forthcoming generation of AChE inhibitors 12. Hybrid inhibitors 13. AChR-targeted drugs for AD treatment 13.1 mAChR muscarinic receptors and antagonists 154 13.2 Semisynthetic and synthetic congeners of ACh antagonists 156 References 158 14. Cholinergic neuromuscular junction and its blocking agents (blockers) 15. Nonadrenergic and noncholinergic (NANC) NTs 16. Protein kinase inhibitors for treatment of AD 17. Inhibition of cholinergic inflammation via AChE inhibitor interaction with α4β2 nAChR and α7nAChR, not AChE enzyme inhibition 18. NMDA and non-NMDA receptor antagonism for ADmtreatment 19. Challenges in recent AD therapeutic approaches 20. Identification and application of biomarkers for AD 21 Artificial intelligence (AI)-assisted AD target and drug discovery 22. Conclusion and perspectives Section 2. Natural alkaloidal and non-alkaloidal anti-AChE and anti- Alzheimer’s disease compounds in the symptomatic intimation of Alzheimer’s disease 23. Introduction 24. Current bioactive molecules in Alzheimer’s disease therapy 25. Emerging lead compounds from naturally occurring molecules for Alzheimer’s disease therapy 26. Natural antiAChE compounds for Alzheimer’s disease therapy 27. Molecular docking simulation for consistency between SAR results and in vitro AChE inhibitory activities 28. Conceptual search for MTDs of plant natural compounds for multifactorial Alzheimer’s disease therapy 29. AChE inhibitors in daily consumable cereals and food resources 30. Conclusion and perspective Section 3. Marine AChE inhibitors for the symptomatic treatment of Alzheimer’s disease 31. Introduction 32. Localization, structure and cellular function of AChE 33. AChE inhibitors from marine resources 34. Non-ChE inhibitory anti-Alzheimer’s disease compounds 35. Emerging concept of dual-target drug (DTD) and multitarget drug (MTD) in AD pathology and promising AD drugs 36. Conclusion and prospectives Index

Uw winkelwagen

Cholinergic Drugs for Alzheimer's Disease

From Central Cholinergic Neurotransmission to Drug Therapies and Natural Products with Multitarget Actions

Samenvatting

Specificaties

Inhoudsopgave

Net verschenen

Rubrieken

Personen

Trefwoorden